Pfizer (PFE) : Elm Advisors added new position in Pfizer during the most recent quarter end. The investment management firm now holds 7,527 shares of Pfizer which is valued at $273,305 , the company said in a statement filed on Jul 13, 2016 with the SEC.Pfizer makes up approximately 0.25% of Elm Advisors’s portfolio.
Other Hedge Funds, Including , Braver Wealth Management reduced its stake in PFE by selling 4,545 shares or 3.59% in the most recent quarter. The Hedge Fund company now holds 122,089 shares of PFE which is valued at $4,433,052. Pfizer makes up approx 0.74% of Braver Wealth Management’s portfolio.Campbell Newman Asset Management Inc boosted its stake in PFE in the latest quarter, The investment management firm added 7,395 additional shares and now holds a total of 465,752 shares of Pfizer which is valued at $16,911,455. Pfizer makes up approx 3.00% of Campbell Newman Asset Management Inc’s portfolio.Webster Bank N. A. reduced its stake in PFE by selling 1,058 shares or 0.61% in the most recent quarter. The Hedge Fund company now holds 171,152 shares of PFE which is valued at $6,214,529. Pfizer makes up approx 0.89% of Webster Bank N. A.’s portfolio.Gw&k Investment Management boosted its stake in PFE in the latest quarter, The investment management firm added 45,824 additional shares and now holds a total of 1,004,843 shares of Pfizer which is valued at $36,485,849. Pfizer makes up approx 0.74% of Gw&k Investment Management’s portfolio.Curian Capital reduced its stake in PFE by selling 463,954 shares or 63.15% in the most recent quarter. The Hedge Fund company now holds 270,733 shares of PFE which is valued at $9,778,876. Pfizer makes up approx 0.70% of Curian Capital’s portfolio.
Pfizer closed down -0.13 points or -0.35% at $36.64 with 1,69,14,164 shares getting traded on Monday. Post opening the session at $36.69, the shares hit an intraday low of $36.55 and an intraday high of $36.99 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Pfizer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 3, 2016. Analyst had a consensus of $0.55. The company had revenue of $13005.00 million for the quarter, compared to analysts expectations of $12008.32 million. The company’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.
Investors should note that on Jun 23, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Aug 3, 2016 as the ex-dividend date and fixed the record date on Aug 5, 2016. The payable date has been fixed on Sep 1, 2016.
Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .Berenberg Initiated Pfizer on May 12, 2016 to “Hold”, Price Target of the shares are set at $38.Company shares were Reiterated by UBS on May 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $36 .
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.